Luis Fernández Espigares
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luis Fernández Espigares has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Alejandro González
Neurovascular Laboratory, Instituto de Biomedicina deSevilla IBiS/University HospitalVirgen del Rocio/CSIC/University of Seville, Sevilla, Spain
1 shared publicationAlicia Fernández Panadero
Department of Neurology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
1 shared publicationAndrés Hermosín-Gómez
Stroke Unit, Department of Neurology, Virgen del Rocio University Hospital, Sevilla, Spain
1 shared publicationAntonio C. Luque Ambrosiani
1 shared publication- Asier de Albóniga-Chindurza
Neurovascular Laboratory, Instituto de Biomedicina deSevilla IBiS/University HospitalVirgen del Rocio/CSIC/University of Seville, Sevilla, Spain
1 shared publication - Carlota Villar Rodríguez
Stroke Unit, Department of Neurology, Virgen del Rocio University Hospital, Sevilla, Spain
1 shared publication
Latest Publications
- 18 September 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Predicting futile recanalization after mechanical thrombectomy in patients with ischemic stroke and cancer: the CACTUS nomogram
Background: Patients with large vessel occlusion (LVO) and a history of cancer have worse long-term outcomes after mechanical thrombectomy (MT) despite similar reperfusion rates. We aimed to develop a clinical prognostic score to predict futile recanalization (FR) in this population. Methods: We retrospectively analyzed a single-center prospective registry (ARTISTA) of patients with LVO and active or previous cancer who underwent MT between January 2021 and December 2023. The primary outcome was FR, defined as successful angiographic reperfusion (expanded Thrombolysis in Cerebral Infarction (eTICI) ≥2b) with poor functional outcome (modified Rankin Scale (mRS) ≥3) at 90 days. A clinically prespecified logistic regression model was developed to predict FR. Model performance was assessed, and internal validation was performed using bootstrap resampling and repeated cross-validation. An expanded penalized least absolute shrinkage and selection operator (LASSO) model was evaluated as a secondary analysis and a nomogram was derived from the final model. Results: Of 1584 patients who underwent MT during the study period, 167 patients with a history of cancer met the eligibility criteria for analysis. FR occurred in 50.9% of patients. A clinically prespecified prediction model included age, pre-stroke mRS score, admission National Institutes of Health Stroke Scale (NIHSS) score, and metastatic disease. A higher pre-stroke mRS score (adjusted OR (aOR) 1.84, 95% CI 1.09 to 3.21; P=0.025), higher admission NIHSS score (aOR 1.11 per point, 95% CI 1.05 to 1.17; P<0.001), and metastatic disease (aOR 8.38, 95% CI 2.77 to 31.93; P<0.001) were independently associated with FR. Internal bootstrap validation yielded an optimism-corrected AUC of 0.758 and a Brier score of 0.206. An optimism-corrected nomogram was derived for clinical use. Conclusion: The CACTUS prediction model showed adequate predictive performance for FR, and the derived nomogram may serve as a practical tool for individualized risk assessment in patients with LVO who are candidates for MT and have a history of cancer.
- 18 September 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Predicting futile recanalization after mechanical thrombectomy in patients with ischemic stroke and cancer: the CACTUS nomogram
Background: Patients with large vessel occlusion (LVO) and a history of cancer have worse long-term outcomes after mechanical thrombectomy (MT) despite similar reperfusion rates. We aimed to develop a clinical prognostic score to predict futile recanalization (FR) in this population. Methods: We retrospectively analyzed a single-center prospective registry (ARTISTA) of patients with LVO and active or previous cancer who underwent MT between January 2021 and December 2023. The primary outcome was FR, defined as successful angiographic reperfusion (expanded Thrombolysis in Cerebral Infarction (eTICI) ≥2b) with poor functional outcome (modified Rankin Scale (mRS) ≥3) at 90 days. A clinically prespecified logistic regression model was developed to predict FR. Model performance was assessed, and internal validation was performed using bootstrap resampling and repeated cross-validation. An expanded penalized least absolute shrinkage and selection operator (LASSO) model was evaluated as a secondary analysis and a nomogram was derived from the final model. Results: Of 1584 patients who underwent MT during the study period, 167 patients with a history of cancer met the eligibility criteria for analysis. FR occurred in 50.9% of patients. A clinically prespecified prediction model included age, pre-stroke mRS score, admission National Institutes of Health Stroke Scale (NIHSS) score, and metastatic disease. A higher pre-stroke mRS score (adjusted OR (aOR) 1.84, 95% CI 1.09 to 3.21; P=0.025), higher admission NIHSS score (aOR 1.11 per point, 95% CI 1.05 to 1.17; P<0.001), and metastatic disease (aOR 8.38, 95% CI 2.77 to 31.93; P<0.001) were independently associated with FR. Internal bootstrap validation yielded an optimism-corrected AUC of 0.758 and a Brier score of 0.206. An optimism-corrected nomogram was derived for clinical use. Conclusion: The CACTUS prediction model showed adequate predictive performance for FR, and the derived nomogram may serve as a practical tool for individualized risk assessment in patients with LVO who are candidates for MT and have a history of cancer.
- 20 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 107023
Inter-assay variability in anti–JC virus testing for natalizumab: A Spanish cohort
- 20 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 107023
Inter-assay variability in anti–JC virus testing for natalizumab: A Spanish cohort
- 1 October 2025
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 39 (4) , 324-327
Clinical Presentation of Inflammatory Amyloid Angiopathy in Seville, Spain
ICAA is an underdiagnosed inflammatory response to β-amyloid (Aβ) deposition in the cortical and leptomeningeal microcirculation, and is clinically heterogeneous. We present a retrospective observational study conducted at a tertiary center from 2011 to 2024, including 11 patients who met the 2016 clinicoradiological criteria. Eleven patients were included in the study. Seven patients (64%) were female. The mean age was 70.6 years. The most frequent symptoms were seizures (n=9, 82%) and headaches (n=8, 73%). All patients presented with cortical microbleeds and white matter hyperintensities in MRI. Cortical and leptomeningeal biopsies were performed in 2 cases due to diagnostic uncertainty. Corticosteroid therapy was used in 9 (82%) patients, but clinical relapse occurred in 55%, and 45% were functionally dependent after 1 year. This case series highlights the heterogeneous clinical and radiologic presentation of ICAA and the challenges in its diagnosis and management, highlighting the need for standardized therapeutic approaches and further research to improve its prognosis.
- 1 October 2025
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 39 (4) , 324-327
Clinical Presentation of Inflammatory Amyloid Angiopathy in Seville, Spain
ICAA is an underdiagnosed inflammatory response to β-amyloid (Aβ) deposition in the cortical and leptomeningeal microcirculation, and is clinically heterogeneous. We present a retrospective observational study conducted at a tertiary center from 2011 to 2024, including 11 patients who met the 2016 clinicoradiological criteria. Eleven patients were included in the study. Seven patients (64%) were female. The mean age was 70.6 years. The most frequent symptoms were seizures (n=9, 82%) and headaches (n=8, 73%). All patients presented with cortical microbleeds and white matter hyperintensities in MRI. Cortical and leptomeningeal biopsies were performed in 2 cases due to diagnostic uncertainty. Corticosteroid therapy was used in 9 (82%) patients, but clinical relapse occurred in 55%, and 45% were functionally dependent after 1 year. This case series highlights the heterogeneous clinical and radiologic presentation of ICAA and the challenges in its diagnosis and management, highlighting the need for standardized therapeutic approaches and further research to improve its prognosis.